Investors & Media

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Flex Pharma to Report Second Quarter 2015 Results on August 5, 2015

BOSTON--(BUSINESS WIRE)--Jul. 29, 2015-- Click to Tweet this News

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions, today announced that it will report its financial results for the quarter ended June 30, 2015 on Wednesday, August 5, 2015 before the U.S. financial markets open. The Company will host a conference call and webcast at 9:00 a.m. ET to discuss second quarter 2015 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).

A live webcast may be accessed in the Investors section of the Company's website at www.flex-pharma.com. Please log on to the Flex Pharma website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Flex Pharma's website for three months.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers. In addition, the proprietary treatment has been demonstrated to prevent muscle cramps in an initial study of athletes participating in high intensity sports.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Source: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications
irdept@flex-pharma.com